

**SUPPLEMENTARY INFORMATION:** The invention relates to methods, compositions and kits for use in protection against and/or treatment of chemical warfare nerve agent (CWNA) and/or organophosphate (OP) pesticide/insecticide exposure. In particular, the present invention relates to methods, compositions and kits for treating, preventing, inhibiting or reducing a seizure, status epilepticus, neuropathogenesis, or a neuropathology caused by exposure to a CWNA or an OP pesticide/insecticide using (a) imidazenil, (b) a combination treatment comprising imidazenil and [+-]Huperzine A, (c) a combination treatment comprising imidazenil and [-]-Huperzine A, or (d) a combination treatment comprising imidazenil, [+-]Huperzine A and [-]-Huperzine A.

**Brenda S. Bowen,**

*Army Federal Register Liaison Officer.*

[FR Doc. 2014-00286 Filed 1-10-14; 8:45 am]

**BILLING CODE 3710-08-P**

## DEPARTMENT OF DEFENSE

### Department of the Army

#### **Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Measurements of the Inhibition of Synaptic Activity (MISA) To Detect, Study and Evaluate All Active Botulinum Neurotoxin Serotypes**

**AGENCY:** Department of the Army, DoD.

**ACTION:** Notice.

**SUMMARY:** Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/851,599, entitled "Measurements of the Inhibition of Synaptic Activity (MISA) to Detect, Study and Evaluate All Active Botulinum Neurotoxin Serotypes," filed on March 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** The invention relates to measurements of spontaneous or evoked electrical activity in networked populations of primary neurons or stem cell-derived neurons as a rapid, sensitive assay for the presence of functional botulinum neurotoxin (BoNT) in various matrices.

**Brenda S. Bowen,**

*Army Federal Register Liaison Officer.*

[FR Doc. 2014-00283 Filed 1-10-14; 8:45 am]

**BILLING CODE 3710-08-P**

## DEPARTMENT OF DEFENSE

### Department of the Army

#### **Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients**

**AGENCY:** Department of the Army, DoD.

**ACTION:** Notice.

**SUMMARY:** Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/733,938, entitled "Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients," filed on December 6, 2012. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** The invention relates to low fat, high protein, high carbohydrate enteral nutritional formulations for use in providing the complete nutritional needs of subjects with severe burn, methods of providing nutritional support to burn patients using these formulations, and methods of making the same. These complete enteral nutritional formulations are polymeric, concentrated, and do not contain added arginine. In addition, these enteral nutritional formulations are

homogeneous solutions that flow through tubing well.

**Brenda S. Bowen,**

*Army Federal Register Liaison Officer.*

[FR Doc. 2014-00287 Filed 1-10-14; 8:45 am]

**BILLING CODE 3710-08-P**

## DEPARTMENT OF DEFENSE

### Department of the Army

#### **Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Contact Pathway and Tissue Kallikrein Inhibitors Can Prevent/Reduce Leakage Caused by Hantavirus**

**AGENCY:** Department of the Army, DoD.

**ACTION:** Notice.

**SUMMARY:** Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/851,573, entitled "Contact Pathway and Tissue Kallikrein Inhibitors can Prevent/Reduce Leakage Caused by Hantavirus," filed on March 15, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

**ADDRESSES:** Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:** The invention relates to treatment of vascular leakage symptoms infected with the Hantavirus using drugs that are already FDA approved.

**Brenda S. Bowen,**

*Army Federal Register Liaison Officer.*

[FR Doc. 2014-00285 Filed 1-10-14; 8:45 am]

**BILLING CODE 3710-08-P**

## DEPARTMENT OF DEFENSE

### Defense Acquisition Regulations System

[Docket Number DARS-2013-0038]

#### **Submission for OMB Review; Comment Request**

**ACTION:** Notice.